News
LTRN
3.860
+5.18%
0.190
Weekly Report: what happened at LTRN last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at LTRN last week (0608-0612)?
Weekly Report · 06/15 09:16
Lantern Pharma files to sell 2.24M shares of common stock for holders
TipRanks · 06/12 20:36
Lantern Pharma Announces Selling Stockholders May Sell Up To 2.24M Shares Of Common Stock
Benzinga · 06/12 20:34
LANTERN PHARMA - SELLING STOCKHOLDERS MAY SELL UP TO 2.24 MLN SHARES OF COMMON STOCK - SEC FILING
Reuters · 06/12 20:32
Weekly Report: what happened at LTRN last week (0601-0605)?
Weekly Report · 06/08 09:15
New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET
Barchart · 06/06 06:20
Lantern Pharma reports data, updates from Phase 2 Harmonic trial on LP-300
TipRanks · 06/02 13:02
Lantern Pharma Reports Clinical Data And Updates From Ongoing Phase 2 HARMONIC Trial Evaluating LP-300 In Combination With Carboplatin And Pemetrexed In Patients With EGFR Exon 21 L858R-Mutant NSCLC
Benzinga · 06/02 12:19
Lantern Pharma says Phase 2 HARMONIC trial shows LP-300 lifts median PFS to 8.9 months in EGFR L858R lung cancer patients treated up to six cycles
PUBT · 06/02 12:13
LANTERN PHARMA - OVER 70% OF L858R PATIENTS SHOW TUMOR REDUCTION; 77% CLINICAL BENEFIT RATE
Reuters · 06/02 12:13
Lantern Pharma posts LP-300 Phase 2 HARMONIC trial presentation in EGFR L858R NSCLC
PUBT · 06/02 11:06
Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress
TipRanks · 06/02 10:47
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Barchart · 06/02 07:13
Weekly Report: what happened at LTRN last week (0525-0529)?
Weekly Report · 06/01 09:17
Weekly Report: what happened at LTRN last week (0518-0522)?
Weekly Report · 05/25 09:17
New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, and Global Workforce Technology
Barchart · 05/23 07:25
Lantern receives successful response to Type C meeting from FDA on LP-300
TipRanks · 05/19 11:41
Lantern Pharma Receives Successful Response To Its Recent FDA Type C Meeting Request Focused On The Ongoing Phase 2 HARMONIC Trial Of LP-300 In Never-Smokers With Advanced Non-Small Cell Lung Cancer Adenocarcinoma
Benzinga · 05/19 11:37
Lantern Pharma shifts LP-300 Phase 2 HARMONIC trial to single-arm L858R focus
PUBT · 05/19 11:31
More
Webull provides a variety of real-time LTRN stock news. You can receive the latest news about Lantern Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ ML algorithms. It is engaged in the development of its pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate program. Its portfolio includes a Phase II clinical program (LP-300) in NSCLC focused on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; planned Phase I b/II trials (LP-184) in precision, biomarker-defined solid tumors, and an ongoing Phase II program in hematologic malignancies and adult soft tissue sarcomas (LP-284). It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.